Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7342248 | 0.98 | ALDH1A1 (0.40) | ALDH1A1LMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL7342254 | 0.98 | ALDH1A1 (0.40) | ALDH1A1LMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL7345170 | 0.97 | MMP2 (0.40) | ALDH1A1LMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL28294340 | 0.86 | KMT2A (0.40) | ALDH1A1LMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL7345167 | 0.86 | LMNA (0.37) | ALDH1A1LMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL6535237 | 0.84 | SMN1; SMN2 (0.41) | ALDH1A1LMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL29033834 | 0.83 | ALDH1A1 (0.40) | ALDH1A1LMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL757884 | 0.83 | TP53 (0.48) | ALDH1A1LMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL8429495 | 0.82 | LMNA (0.39) | ALDH1A1LMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL8429588 | 0.82 | LMNA (0.39) | ALDH1A1LMNATP53SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119947713-A | Composition for accurate cancer treatment and accurate cancer treatment method | 斯坦尼斯瓦夫·R·布尔津斯基 | 2025-05-06 | — | — | CN | claimed |
| CN-119947713-A | Composition for accurate cancer treatment and accurate cancer treatment method | 斯坦尼斯瓦夫·R·布尔津斯基 | 2025-05-06 | — | — | CN | disclosed |
| US-6943192-B2 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate | BURZYNSKI STANISLAW R (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1098643-B1 | PHENYLACETYLGLUTAMINE, PHENYLACETYLISOGLUTAMINE, AND/OR PHENYLACETATE FOR THE TREATMENT OF NEOPLASTIC DISEASES | BURZYNSKI STANISLAW R (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20010044466-A1 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate | BURZYNSKI STANISLAW R (US) | 2001-11-22 | — | — | US | disclosed |
| US-6258849-B1 | DRUG COMPOSITION WITH CARBOXYALKYL DIAMIDES WITH PHENYL OR NAPHTHYL GROUPS | BURZYNSKI STANISLAW R (US) | 2001-07-10 | — | — | US | disclosed |
| EP-1098643-A2 | TREATMENT REGIMEN FOR ADMINISTRATION OF PHENYLACETYLGLUTAMINE, PHENYLACETYLISOGLUTAMINE, AND/OR PHENYLACETATE | BURZYNSKI, Stanislaw R. (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004894-A2 | TREATMENT REGIMEN FOR ADMINISTRATION OF PHENYLACETYLGLUTAMINE, PHENYLACETYLISOGLUTAMINE, AND/OR PHENYLACETATE | BURZYNSKI STANISLAW R (US) | 2000-02-03 | — | — | WO | disclosed |
| US-4559325-A | ANTITUMOR AGENTS | BURZYNSKI STANISLAW R (US) | 1985-12-17 | — | — | US | disclosed |
| US-4558057-A | URINE EXTRACTS | BURZYNSKI STANISLAW R (US) | 1985-12-10 | — | — | US | disclosed |
| US-4470970-A | ANTITUMOR AND-CARCINOGENIC AGENT EXTRACTED FROM URINE | BURZYNSKI STANISLAW R | 1984-09-11 | — | — | US | disclosed |
| EP-0069232-A2 | Pharmaceutical composition comprising phenyl acetyl glutamine,a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)piperidine-2,6-dione,a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)piperidine-2,6-dione | BURZYNSKI, Stanislaw R. (US) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044466-A1 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate | ACACA, PGAM1, GOT1 | ALDH1A1 253/4885LMNA 3949/4885TP53 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.